KRAS mutational status of endoscopic biopsies matches resection specimens
- Qing-Hua Yang1,
- Jason Schmidt1,
- Genvieve Soucy2,
- Robert Odze2,
- Liza Dejesa-Jamanila3,
- Keely Arnold3,
- Christine Kuslich3,
- Richard Lash1
- 1Miraca Research Institute, Miraca Life Sciences, Irving, Texas, USA
- 2Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
- 3Caris Life Sciences, Phoenix, Arizona, USA
- Correspondence to Dr Richard Lash, Miraca Research Institute, Miraca Life Sciences, 6655 N. MacArthur Boulevard, Irving, TX 75039, USA;
Contributors All authors contributed substantially to conception and design, analysis and interpretation of data, drafting the article, revising it critically for important intellectual content and final approval of the version to be published.
- Accepted 16 February 2012
- Published Online First 29 March 2012
Aims This study was performed to determine systematically whether KRAS mutational analysis in biopsy tissue is a reliable indicator of KRAS status in subsequent corresponding resection specimens.
Methods 30 colorectal cancer (CRC) patients with biopsy and corresponding subsequent surgical resection specimens were studied. KRAS mutational analysis was performed on each biopsy sample as well as two separate samples from each resection specimen by PCR and Sanger sequencing.
Results Overall, KRAS mutations were identified in 12/30 (40%) of the tumours. There was 100% correlation between biopsy and resection specimens regarding the presence or absence of KRAS mutations. In fact, the same point mutation was identified in both biopsy and corresponding resection specimens in 12/12 (100%) cases. In addition, in two cases, there were two different point mutations detected within the same biopsy specimen.
Conclusion This study shows perfect correlation between KRAS mutation status in biopsy and resection specimens from an individual patient, and suggests that biopsy material is adequate for KRAS mutational analysis in CRC patients.
- Comparison study
- endoscopic biopsy
- GI neoplasms
- KRAS mutational analysis
- laboratory tests
- surgical resection specimen
- tumour biology
Competing interests None.
Patient consent Obtained.
Ethics approval Internal review board approval for the study was obtained from Brigham and Women's Hospital in Boston, Massachusetts, USA.
Provenance and peer review Not commissioned; externally peer reviewed.